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Abstract
The MC1R gene is a key regulator of skin pigmentation. We aimed to evaluate the association 
between MC1R variants and the risk of sporadic cutaneous melanoma (CM) within the M-SKIP 
project, an international pooled-analysis on MC1R, skin cancer and phenotypic characteristics. 
Data included 5,160 cases and 12,119 controls from 17 studies. We calculated a Summary Odds 
Ratio (SOR) for the association of each of the nine most studied MC1R variants and of variants 
combined with CM by using random-effects models. Stratified analysis by phenotypic 
characteristics were also performed.
Melanoma risk increased with presence of any of the main MC1R variants: the SOR for each 
variant ranged from 1.47 (95%CI: 1.17–1.84) for V60L to 2.74 (1.53–4.89) for D84E. Carriers of 
any MC1R variant had a 66% higher risk of developing melanoma compared to wild-type subjects 
(SOR; 95%CI: 1.66; 1.41–1.96), and the risk attributable to MC1R variants was 28%. When taking 
into account phenotypic characteristics, we found that MC1R–associated melanoma risk increased 
only for darker-pigmented Caucasians: SOR (95%CI) was 3.14 (2.06–4.80) for subjects with no 
freckles, no red hair and skin type III/IV.
Our study documents the important role of all the main MC1R variants in sporadic CM and 
suggests that they have a direct effect on melanoma risk, independently on the phenotypic 
characteristics of carriers. This is of particular importance for assessing preventive strategies, 
which may be directed to darker-pigmented Caucasians with MC1R variants as well as to lightly-
pigmented, fair-skinned subjects.
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Introduction
Starting from the 20th century, both incidence and mortality for cutaneous melanoma (CM) 
has increased among populations of European descent and the estimated annual melanoma 
incidence rate in the world is around 2.8 per 100.000.1 Of the three most prevalent types of 
skin cancer, melanoma is the most lethal, with a five-year survival rate for metastatic 
melanoma of 11%.2 Because of melanoma’s high incidence and poor treatment outcome for 
metastatic disease, development of early detection and preventive strategies are of the 
highest importance.
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Among risk factors for CM, epidemiological studies highlighted the role of sun exposure, 
and of personal characteristics, such as fair skin, light hair and eyes color, high number of 
melanocytic naevi, and family history of melanoma.3–5 Twins studies estimated that genetic 
factors provide a contribution to CM risk of 18–55%, and familial melanoma was estimated 
to account for approximately 10% of new cases.6
The melanocortin-1-receptor gene (MC1R, MIM#155555) is the most common low risk 
susceptibility gene for melanoma and a key regulator of skin pigmentation. It is located on 
chromosome 16q24.3 and encodes for a seven pass transmembrane G-protein coupled-
receptor of 317 amino acids, positively coupled to adenylate cyclase to increase cAMP 
levels upon binding its endogenous ligand, the α-melanocyte-stimulating hormone (α-
MSH).7 Binding of α-MSH to the functional MC1R on melanocytes stimulates the synthesis 
of eumelanin pigments8 resulting in significant increases of the ratio of black/brown 
eumelanin to red/yellow phaeomelanin pigments. While eumelanin has been shown to be 
photoprotective, phaeomelanin is poorly photoprotective and may even contribute to cancer 
risk through the production of free radicals in response to UV exposure.9 The MC1R gene 
locus is highly polymorphic in populations of European origins, with more than 80 variants 
identified.10 MC1R variant alleles, resulting in amino acid substitutions that have been 
shown to reduce receptor function11–13, result in a quantitative shift of melanin synthesis 
from eumelanin to phaeomelanin,7 and determination of the so called “red hair color” 
(RHC) phenotype, characterized by the co-occurrence of fair skin, red hair, freckles and UV 
irradiation (UVR) sensitivity (poor tanning response and solar lentigines).
Several studies in different populations have reported that the risk of melanoma is higher 
among individuals who carry MC1R variant alleles. More recently, meta-analyses and 
genome-wide association studies (GWAS) confirmed this finding14–18. Although melanoma 
risk attributable to MC1R may arise through the determination of the tanning response of 
skin to UV light, some studies and a recent meta-analysis15 observed that MC1R–associated 
CM relative risk was stronger in darkly-pigmented subjects and for those with lower levels 
of recreational sun exposure. These results suggest that MC1R variants may partly mediate 
their effect through biological pathways that are independent of pigmentation and UV 
exposure. In keeping with this possibility, wild type (WT) MC1R has been shown to trigger 
DNA repair mechanisms and antioxidant defenses in UVR-exposed melanocytes, while 
inactivated MC1R, resulting in production of pheomelanin, increases damage from reactive 
oxygen species, even in the absence of UV-exposure.19,20 Those mechanisms may be of 
importance for at least some of the variant alleles.
Although the previous meta-analyses and GWAS gave reliable evidence of a role of MC1R 
in CM development, the lack of access to individual epidemiological information precluded 
in-depth investigations, including the assessment of the role of possible confounders, the 
estimation of melanoma risk according to different MC1R variants compared to WT 
subjects, and stratification for phenotypic characteristics. These investigations are in fact 
crucial for sporadic CM, which represents up to 95% of melanoma cases and is a complex 
and heterogeneous disease, probably the result of interactions between genetic, phenotypic 
and environmental factors.
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The aim of this work is to evaluate the association between specific and combined MC1R 
variants and the risk of sporadic CM, and to evaluate whether risk estimates varied 
according to different phenotypic characteristics through a large multicenter pooled-analysis 
of individual data from the Melanocortin-1 receptor gene, SKin cancer and Phenotypic 
characteristics (M-SKIP) project.
Material and methods
Data for the present analyses were gathered through the M-SKIP project. A description of 
the project was previously published.21 Briefly, we searched for published and unpublished 
epidemiological studies on MC1R variants, sporadic CM, non-melanoma skin cancer 
(NMSC), and phenotypic characteristics associated with melanoma. Original individual data 
on participants in each identified study were requested from principal investigators. From 
May 2009 to December 2010, 43 investigators were contacted and 31 (72%) agreed to 
participate. Non-participant investigators where those who either did not reply to our 
invitation letter, were not able to retrieve the original dataset and/or were not interested in 
the project. More details are reported elsewhere21. Participant investigators sent their data 
along with a signed statement declaring that their original study was approved by an Ethics 
Committee and/or that study subjects provided a written consent to participate in the original 
study. Quality controls and data coding were performed, and the pooled database was 
created, including data on 7,806 CM cases, 3,151 NMSC cases and 14,875 controls.
For the purpose of the present study, we selected from the M-SKIP database all the 
melanoma case-control studies (N=17)15, 22–36, thus including data on 5,160 CM cases and 
12,119 controls overall. Case-only or control-only studies, and studies on NMSC were 
excluded from the present analysis.
Statistical analysis
In order to evaluate the representativeness of the M-SKIP dataset, the main study population 
characteristics reported in publications of non-participating investigators were extracted and 
compared with those of studies included in the pooled-analysis, by the Chi-Square test for 
categorical variables and by the Wilcoxon two-sample test for continuous variables. We also 
assessed possible participation bias by drawing funnel plots and by Egger's test. We verified 
the departure of frequencies of each MC1R variant from expectation under Hardy-Weinberg 
(HW) equilibrium by the Chi Square test in controls for each included study.
We calculated study-specific Odds Ratio (OR) with 95% Confidence Interval (CI) by 
applying logistic regression to the data from each study. Beyond MC1R, each model 
included, if available, the following covariates: age, sex, intermittent and chronic sun 
exposure, lifetime and childhood sunburns, family history of melanoma, number of common 
total body naevi count and presence of atypical naevi. Because of different definitions of 
covariates between studies, particular attention was given to recoding and standardizing the 
variables in the M-SKIP database, as previously discussed.21 For each study, we imputed 
missing data with multiple imputation models for variables with less than 20% of missing 
data, by using the iterative Markov chain Monte Carlo method. For each of the nine most 
studied MC1R variants (V60L, D84E, V92M, R142H, R151C, I155T, R160W, R163Q, 
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D294H), we tested different inheritance models and found that the dominant model was the 
one with the lowest Akaike's Information Criterion for almost all the studies and variants, 
therefore we assumed this model of inheritance in the pooled-analyses. We performed two 
different variant-specific analyses: the first one included the 12 studies in which MC1R was 
sequenced, for which we could identify the WT subjects as reference category; the second 
one included all the 17 studies and used as reference category for each variant the subjects 
without that variant. For studies which sequenced the MC1R gene, beyond the MC1R 
variant-specific OR, we estimated the OR associated with the most frequently observed 
haplotypes. Haplotype frequencies for the nine most common variants were calculated with 
the EM algorithm using UNPHASED, version 3.1.7. Rare haplotypes (frequency<0.005) 
were ignored. In addition, we took into account all the identified (common and rare) variants 
and calculated the OR for 1) carrying at least one MC1R variant compared to WT, 2) 
carrying just one and carrying ≥2 MC1R variants compared to WT. Finally, a MC1R score 
was calculated, based on classification of likely pathogenicity of variants using 
bioinformatics analysis as implemented by Davies et al:37 briefly, the score was calculated 
by summing across the MC1R alleles, giving a value of 1 to “r” and 2 to “R” variants.
Following the two-stage analysis approach, we pooled study-specific OR with random-
effects model, using the DerSimonian-Laird method. When there were more than one OR 
calculated in a single study (i.e. analysis by MC1R score), the correlation between the ORs 
was taken into account by using a multivariate approach previously described.38 We 
evaluated homogeneity among study-specific estimates by the Q statistic and I-Square, 
which represents the percentage of total variation across studies that is attributable to 
heterogeneity rather than to chance. When a significant heterogeneity was detected, we 
performed meta-regression to assess the influence on Summary Odds Ratio (SOR) of 
different study features, such as publication year, study area, genotyping methodology, 
deviation from HW equilibrium, source of controls, and source of DNA. In order to evaluate 
the robustness of the results, we also examined changes in SOR after exclusion of specific 
studies, and we compared the pooled-OR obtained on the M-SKIP dataset with the meta-OR 
calculated by pooling risk estimates reported in studies from not-participating investigators. 
This latter meta-OR was also obtained with DerSimonian-Laird random-effects models.
We computed the attributable risk in the population for each of the nine MC1R variants 
listed above and for the presence of at least one MC1R variant by using the Miettinen’s 
formula: (OR-1/OR) × proportion of cases exposed, with the corresponding 95%CI.
Finally, in order to investigate whether the observed association between MC1R variants and 
melanoma varied according with different phenotypic characteristics, we performed 
stratified analysis. We defined subjects with RHC phenotype as those with either red hair 
color, freckles or high sun sensitivity (skin type I or II according to the Fitzpatrick 
classification), and as darker-pigmented individuals those subjects with none of the above 
phenotypic characteristics. The hypothesis of homogeneity of ORs among strata was tested 
by meta-regression models with random-effects and restricted maximum likelihood 
estimates, after the calculation of strata-specific OR in each study. The correlation between 
the ORs calculated in the same studies was taken into account by using the multivariate 
approach proposed by van Houwelingen et al.38
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P-values <0.05 were considered statistically significant for all the tests but Q statistic, where 
p-values<0.10 were considered statistically significant. Both the false discovery rate 
approach and the more conservative Bonferroni correction were also used to take into 
account the problem of multiple comparisons. The analysis was carried out by using the 
software SAS (version 9.2) and STATA (version 11.2).
Results
Studies included in our pooled-analysis did not differ from studies from not-participating 
investigators according to publication period, study area, phenotype assessment, source of 
controls, genotyping methodology, mean age of cases and controls, sex distribution of cases 
and controls.
Among the 17 studies included in the pooled-analysis, no deviation from HW equilibrium 
was observed for the following MC1R variants: V60L, D84E, V92M, I155T, and R163Q. 
Deviation from HW equilibrium was observed in one study34 for the R142H variant, in 
four23,26,27,33 for R151C variant, in two studies29,34 for R160W variant, and in one study29 
for D294H variant.
Complete sequencing analysis of the MC1R coding region was performed in 12 
studies15,22,24,26–28,30,31,33,35,36, while in the remaining five studies MC1R was genotyped 
by SNaPshot23,29,34, Restriction Fragment Length Polymorphisms25 or allele discrimination 
assay.32
A description of the studies included in the pooled-analysis is presented in Table 1. Studies 
were published between 2001 and 2012; the majority were carried out in Europe (N=13, 
76%), mainly in the southern countries (N=7, 41%), followed by USA (N=3, 18%) and 
Australia (N=1, 6%). In 13 studies (76%) healthy controls were recruited, while in the 
remaining four (24%) hospital controls were included. Overall, the average age of controls 
was higher than that of cases (62 versus 53 years), while the percentage of males was the 
same for both cases and controls (44%). Individual information on age, sex and family 
history of melanoma was available for each study, while further confounders differed 
between studies.
Association between single MC1R variants and melanoma
The most prevalent MC1R variants in the M-SKIP database were nine: V60L, D84E, V92M, 
R142H, R151C, I155T, R160W, R163Q, D294H. When we compared carriers of each 
variant with WT subjects using study-specific ORs and combined ORs, we found that CM 
risk significantly increased for carriers of any of the nine MC1R studied variants, with SOR 
(95%CI) ranging from 1.47 (1.17–1.84) for V60L to 2.74 (1.53–4.89) for D84E (Figure 1 
and Table 2). After adjusting for multiple comparisons, all the p-values were still significant 
following the false discovery rate approach, while the association between I155T variant and 
melanoma was not confirmed after the more conservative Bonferroni correction (adjusted p-
value: 0.08). The related attributable risk (AR) is presented in Figure 2. The highest AR was 
observed for R151 variant (8.9%), followed by R160W (8.3%) and V60L (8.2%) variants. In 
Table 2 we compared the results obtained in the 12 studies with WT as reference category 
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with those obtained in the whole set of 17 studies and using, as reference group for each 
variant, the subjects without that variant. For this latter analysis, a significant association 
with CM was observed for all the MC1R variants but V60L, I155T and R163Q. It should be 
noted that the reference group of this latter analysis included, for each studied variant, both 
WT and any other MC1R variant.
Funnel plots for each MC1R variant are presented in Supplemental Figure 1 for the whole 
set of studies. We found some evidence of participation bias for the R163Q variant, with a 
borderline p-value (0.05).
Significant heterogeneity among the 12 risk estimates with WT as reference category was 
found for V60L (I2:50.9%, Q statistic p-value:0.02) and R142H (I2:49.3%, Q statistic p-
value:0.03) (Figure 1). Variability in publication year, study area, genotyping methodology, 
deviation from HW equilibrium, source of controls, and source of DNA did not seem to 
explain the observed heterogeneity. Sensitivity analyses showed that the heterogeneity may 
be attributable to single studies: when we excluded the studies that lied out of the 
corresponding funnel plots, we obtained similar pooled-ORs than the original analyses, but 
with no more evidence of heterogeneity among study-specific estimates. For the analysis 
with WT as reference category SORs (95%CI) increased to 1.54 (1.27–1.88) and 2.76 (1.71–
4.45) for V60L (excluding26) and R142H (excluding15), respectively; I2 (Q statistic p-value) 
were, respectively, 33.6% (p=0.13) and 29.3%, (p=0.18).
Meta-ORs calculated for studies not included in the M-SKIP project were similar to those 
obtained from our pooled-analysis on the whole dataset for all but R151C variant, for which 
it was significantly higher than our pooled-OR (meta regression p-value=0.05).
Association between combined MC1R variants and melanoma
SOR for the most common haplotypes were reported in Supplemental Table 1 for the 12 
studies in which MC1R was sequenced. Results were similar to those observed for the 
single-variant analysis, with the higher SOR (3.05; 95%CI: 1.56–5.98) observed for the 
haplotype corresponding to a single mutation at rs1805006 (D84E).
We found that subjects carrying at least one MC1R variant had a significantly increased risk 
of CM, with SOR (95%CI) = 1.66 (1.41, 1.96) (Table 3). The risk attributable to any MC1R 
variant was 28.3%.
Individuals carrying just one MC1R variant had almost 40% increased risk of CM compared 
to WT homozygous subjects (SOR 1.41; 95%CI 1.07–1.87, Table 3), whereas carriers of 
two or more MC1R variants had more than a double risk of CM than WT subjects (SOR 
2.51; 95%CI 1.83–3.44, Table 3).
A significant linear trend was observed for one point increase in MC1R score (per-point 
SOR 1.39; 95%CI 1.31–1.48, p-value <0.0001). SOR (95%CI) increased from 1.24 (0.90–
1.72) to 1.69 (1.21–2.35) to 3.28 (2.22–4.87) and then slightly decrease to 3.12 (1.99–4.91) 
with increasing score from 1 to 4+ (Table 3).
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Analyses stratified by phenotypic characteristics
Results from analyses stratified according by freckles, hair color, skin type and their 
combination for any MC1R variant and for the nine most prevalent MC1R variants are 
reported in Table 4 for seven studies with WT as reference category and information on 
phenotypic characteristics. Stratified analysis for the most common haplotypes are reported 
in Supplemental Table 2.
For subjects with the RHC phenotype, the risk of CM was not independently predicted by 
having MC1R variants: SORs (95%CI) for carriers of any MC1R variant were 1.16 (0.79–
1.72), 0.90 (0.23–3.58), 1.16 (0.73–1.85), and 1.16 (0.88–1.52) for subjects with freckles, 
red hair, skin type I/II, and any of the above phenotypic characteristics, respectively. On the 
contrary, darker-pigmented subjects presented a significantly higher risk of CM associated 
with MC1R variants: SORs (95%CI) for carriers of any MC1R variant were 2.39 (1.60–
3.57), 1.70 (1.20–2.42), 1.89 (1.29–2.78) and 3.14 (2.06–4.80) for subjects with no freckles, 
no red hair, skin type III/IV, and all the above phenotypic characteristics, respectively. This 
trend was observed also when we analyzed each single variant and when we looked 
separately at the 5 southern European studies,24,26–28,36 the USA study15 and the northern 
European study.22 The difference between the strata-specific ORs was statistically 
significant for the analysis on freckles, skin type and the combination of the three RHC 
phenotypic characteristics for any MC1R variant.
Further stratified analyses were performed for skin color and eye color (Supplemental Table 
3). Also for these variables, a constant trend was observed, with higher SORs obtained for 
darker-pigmented subjects compared to lighter-pigmented individuals.
Discussion
Our pooled-analysis identified a significant association with sporadic CM for all the most 
common MC1R variants compared to WT. An unbiased and precise estimate of the risk of 
melanoma in carriers of MC1R variants for different populations of European origins is 
provided for the first time by our group, since in previous large meta-analysis14–16,18 SORs 
were systematically biased toward the null, due to the inclusion of carriers of other MC1R 
variants in the reference category for each variant analysis. The three RHC variants R151C, 
R160W, and D294H were previously associated with CM risk.14,16,18,22,24–26 The 
association of D84E, R142H and I155T with CM was not always identified in single studies, 
probably because of the low frequency of these alleles, but it was confirmed by more 
powerful meta-analyses.14,16,18
An important question raised by these findings refers to the functional characteristics of 
mutant alleles accounting for their association with CM and for their different penetrance. 
The functional properties of WT MC1R, the most common RHC variants, and a few rarer 
variants have been addressed in several independent studies. WT MC1R triggers at least 
three major signal transduction pathways. The Gs protein-dependent activation of the cAMP 
pathway leads to induction of the master melanocyte transcription factor MITF and its 
downstream targets including the melanogenic enzymes.39 Efficient activation of the cAMP 
pathway appears essential for the synthesis of eumelanins and for a normal tanning 
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response.40 In addition, MC1R activation triggers two mitogen-activated protein kinase 
(MAPK) modules, one leading to activation of p38 kinase,41 and the other to the 
extracellular signal-regulated kinases ERK1 and ERK2.42 The functional outputs in 
melanocytes of these two related pathways are poorly understood. Interestingly, whereas 
p38 activation downstream of the MC1R depends on cAMP,41 ERK activation in human 
melanocytic cells appears cAMP-independent.42 Accordingly natural mutations in the 
MC1R gene may have different effects on functional coupling to the cAMP and ERK 
pathways, as confirmed by several studies.43,44
Several independent studies have firmly established that the major RHC alleles are loss-of-
function forms with decreased cAMP signaling,11–13 although they may retain a high 
efficacy for ERK activation.13,42,44 For the D84E, R151C, I155T and R160W receptors 
impairment in cAMP coupling is largely accounted for by reduced cell surface expression. 
Conversely, the R142H and D294H variants show normal or even slightly increased cell 
surface expression,11 and their loss-of-function phenotype is most likely related to an 
inability to properly undergo the agonist-induced transition to the active state and/or to 
impaired coupling to the Gs protein. In any case, inefficient or even absent activation of the 
cAMP pathway downstream of these forms is consistent with impaired eumelanogenesis, 
which may account for their frequent occurrence in individuals with red hair and fair skin. 
This suggests a pigmentary component for their contribution to CM development,14 
whereby tanning ability would be compromised in these individuals and production of 
photoprotective eumelanin would switch towards biosynthesis of photosensitizing 
pheomelanin.
On the other hand, previous meta-analyses14,16,18 reported controversial results for the 
association of V60L, V92M and R163Q variants with CM. It is worthwhile to note that the 
SOR calculated in the present study for all the nine studied variants compared to WT were 
markedly higher than those reported in previous meta-analyses. These differences are 
probably attributable to a bias towards the null in meta-analyses, due to the fact that 
reference category for OR calculation often includes, for each studied variant, both WT and 
any other MC1R variant. Indeed, when we compared the results obtained in our pooled-
analysis, we noted that SORs calculated with WT as the reference category were always 
higher than the corresponding ones obtained by a classical analysis based on presence/
absence of each variant.
A marginal effect of the V92M substitution on the cell surface expression or the ability to 
activate the cAMP and ERK cascades has been reported.11,44 Concerning R163Q, a 
selective decrease in ERK activation has been recently described13 but its functional 
coupling to the cAMP pathway is normal or only slightly modified,45 and this variant is 
highly frequent in Asian populations. V60L allele has been shown to display reduced cell 
surface expression with a corresponding impairment in cAMP activation.11,44 In fact, its 
functional properties are comparable to those of the RHC forms R151C or R160W 
mentioned above.
When we analyzed MC1R variants combined, we observed a significantly higher risk of CM 
both for carriers of one and carriers of two or more variants compared to WT subjects. It has 
Pasquali et al. Page 9













been previously suggested that RHC alleles may act in a recessive manner and that one fully 
functional copy of MC1R may be sufficient to provide normal function;12 however our 
results suggested that CM risk increased even for carriers of just one MC1R variant. When 
we assigned a score to each subject according with the number of R and r alleles, a dose-
response relationship was noted, with SORs significantly higher with increasing score, as 
expected.
A very interesting result of our pooled-analysis was that we observed a significantly higher 
CM risk associated with MC1R variants only for darker-pigmented subjects of European 
origins, while carriers of MC1R variants with RHC phenotype had no increased risk of 
melanoma compared to non carriers. A similar result was observed in previous studies and 
meta-analysis,15,24 which highlighted that the association between some MC1R variants and 
CM was stronger in subjects with dark hair, dark eyes, skin type III/IV, and in subjects who 
reported low recreational sun exposure. A recent meta-analysis on darker-pigmented 
Southern European populations46 also showed that MC1R RHC variants were strong CM 
risk predictors. These results suggest that MC1R variants may mediate their effects, at least 
partially, through biological pathways that are independent on pigmentation, thus providing 
additional information about melanoma risk in people who would not be identified as high 
risk based on their phenotypic characteristics alone. Recent studies implicate MC1R 
signaling in a number of key biological pathways involved in cell cycle control,47 
apoptosis,48 and activation of DNA repair mechanisms and antioxidant defenses.19 
Production of pheomelanin pigments seems associated with increased oxidative DNA 
damage compared with synthesis of eumelanins.49 Further evidence for pheomelanin-
associated increased cellular oxidative stress was obtained in studies of mice carrying a loss-
of-function mutation of the Mc1r gene. These mice have a yellowish pheomelanic hair 
mimicking the human red hair and show higher levels of lipid peroxides, a product of 
reactive oxygen species (ROS)-mediated lipid damage.20 This study provided evidence in 
support of a melanogenetic effect independent of UV exposure. In addition, as discussed 
above, stimulation of MC1R also activates MAPK pathway and regulates target genes 
involved in inflammation through the NF-Kb pathway.50 Thus, interpretation of the effect of 
MC1R alleles in melanoma beyond its role in pigmentation is complex.
A strength of the present pooled-analysis is the large sample size, which gives power to 
detect associations with relatively rare MC1R variants, and to perform stratified analysis by 
phenotypic characteristics at an individual, rather than at a population, level. Moreover, the 
international collaborative nature of the M-SKIP project makes it possible to assess the 
MC1R–related CM risk in various populations and ancestries, thus providing evidence that 
the estimated risk is robust and consistent in different geographical areas. As it was 
previously pointed out,18 a source of heterogeneity between studies in meta-analysis was the 
choice of study comparator group, which is often characterized, for each variant, by people 
without that variant. This practice leads to underestimate the true risk of disease in meta-
analysis, because MC1R variants are very common: 66% of our study population had at least 
one variant. Within our pooled-analysis we were able to compare each variant with WT in 
the 12 studies with MC1R sequenced, and we indeed obtained markedly higher SORs. 
Moreover we were able to study the combined effect of one or more MC1R variants 
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compared to WT subjects, and this would not be usually possible in a meta-analytic context, 
where the analysis of variants combined usually differed from study to study. Finally, we 
could take into account all the available confounders in our centralized statistical analysis, 
with a homogeneous plan of analysis and homogeneous definition of confounders.
Concerning the possible limitations of this study, one drawback is the exclusion of GWAS 
in the first phase of the project. This was done to avoid increasing the heterogeneity of the 
pooled estimate with a different approach. However GWAS may be included in the M-SKIP 
in a second step of the project. Unavailability of information on other genes in most studies 
prevents the analysis of possible gene-gene interactions. The interactions of other low-risk 
loci need to be taken into account for a full assessment of genetic susceptibility to CM. 
Other genes such as SLC45A2, TYR, TYRP1, ASIP, OCA2, XRCC and GSTP1 may also 
contribute to skin cancer susceptibility. Because we carried out a retrospective pooled-
analysis, we did not perform centralized sequencing. However, previous studies37 have 
reported excellent concordance in sequencing data from different centres. Finally, 
differences in the assessment of sun exposure did not allow for the use of this variable in 
stratified analysis, although it remained possible to take it into account for the adjustment for 
confounders.
In conclusion our study remarks the important role of all the main MC1R variants in 
sporadic CM and suggests that they have a direct effect on melanoma risk, independently on 
the phenotypic characteristics of carriers. This is of particular importance for assessing 
preventive strategies, which may be directed to darker-pigmented individuals of European 
origins with MC1R variants as well as to lightly-pigmented, fair-skinned subjects.
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Refer to Web version on PubMed Central for supplementary material.
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Study-specific and pooled-Odds Ratio (OR) with 95% Confidence Intervals (CI) for the 
association between cutaneous melanoma and MC1R variants (A) V60L, (B) D84E, (C) 
V92M, (D) R142H, (E) R151C, (F) I155T, (G) R160W, (H) R163Q, (I) D294H. Reference 
category for each variant comprises WT subjects
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Attributable risks* in the population for cutaneous melanoma according to each MC1R 
variant (percentages with 95% confidence intervals). Reference category for each variant 
comprises WT subjects
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